China-based biotech company Sciwind Biosciencesis preparing to take a critical step in the global obesity treatment market. An experimental GLP-1 receptor agonist developed by the company ecnoglutide for the drug named, For the purpose of licensing and transferring business rights in the United States We are in active talks with an American pharmaceutical company.

Sciwind CEO speaking to Reuters for the first time Mr. Hainoting that the negotiations are still at an early stage and a formal contract has not been concluded, while the drug of the potential American partner is not only for weight loss; multiple indications He said he wanted to improve it for. The name of the interviewed company or the price of the deal has not yet been shared with the public.

What is Ecnoglutide? How Does It Work?

Ecnoglutide is an injection administered once a week GLP-1 receptor agonistdir. This class of drugs is found in the body regulation of blood sugar Provides and appetite suppressant It works by imitating hormones. Novo Nordic using the same mechanism Weg's and Eli Lilly Zepbound These drugs are already leading in the market. However, the high price and access restrictions of these drugs create serious potential for more economical alternatives in the market.

In June 2025 The Lancet Diabetes & Endocrinology According to Phase 3 results published in the journal, obese and overweight individuals using ecnoglutide, on average 10% to 15% experienced weight loss. These rates are comparable to current FDA-approved leading treatments.

SciWind's Strategy: Using Chinese and Australian Data

Sciwind aims to use its extensive data sets from clinical trials in China and Australia in the licensing process in the US. While this has the potential to provide advantages in terms of both time and cost, the FDA absorption and distribution of drugs in different ethnic groups The possibility of requiring additional security is important in the company's planning.

CEO Pan Hai says FDA is most likely”bridging studyIt is called” bridging works He says he will demand it. These studies aim to compare the pharmacokinetics of the drug (how it circulates in the body) between different patient populations. According to SciWind's prediction, along with this process, the entry of ecnoglutide into the US market the earliest three years It can happen within.

Competition Intensifies in GLP-1 Market

In the United States, GLP-1 class drugs have become a rapidly growing market in recent years. The chronic nature of obesity and type 2 diabetes increases the need for effective drugs in this area. However, the annual costs of existing treatments can exceed $15,000, which is a significant burden on both patients and health systems.

Sciwind's drug, a more cost-effective alternative It aims to position itself in this market by offering. The company, outside the strategic licensing partnership in the United States; Latin America, Middle East and Southeast Asia It conducts interviews with potential partners in emerging markets as well.

China Market and Licensing Process

Company for ecnoglutide in China for both weight management as well type 2 diabetes applied for approval for treatment. Although Pan Hai does not give a precise calendar regarding the approval process in China, he emphasizes that the launch of the product to the market is within the medium-term plans. As for pricing, Pan is with the company's current GLP-1 drugs competitive but stable will follow a pricing policy; “They're not going to get into a price war.” He clearly expressed it.

A New Player Arrives in the Global GLP-1 Ecosystem

Global obesity treatment market by 2030 Exceeding $100 billion While expected, GLP-1 class drugs will be the motor power of this growth. But limited supply, high prices and patent protections create gaps in the market. Sciwind thinks it has the scientific infrastructure and clinical data that can fill these gaps.

As a result, SciWind's ecnoglutide project could be not only a growth spurt for a biotech company, but also the birth of a more accessible treatment option for global health systems. The potential licensing process in the US will have a decisive impact on the company's corporate valuation.